Member ID
User Password

Home  About Us  FREE Registration  Benefits  Contact Us  Partners  News  CRA Act

Latest Credit, Finance & Industry News
Global biotech industry faces tight funding [20-06-2012]  
    Email to friends.

The growth of the global biotechnology industry remains challenging with tight funding straining the traditional drug development model despite the industry’s financial performance stabilising.

Ernst & Young said in its “Beyond Borders: Global Biotechnology Report 2012” that the industry globally showed a second straight year of increasingly stable financial performance in 2011.

“For the first time since the start of the global financial crisis, the established biotech markets registered more than 10% revenue growth,” it said in a statement yesterday.

“However, longer-term sustainability remains challenging, with the traditional funding-and-innovation model for pre-commercial biotech firms under unprecedented strain and the industry’s efforts to date to ‘do more with less’ uncertain to deliver significant productivity gains,” it addded.

Ernst & Young’s Global Life Sciences Leader Glen Giovannetti said: “In this capital-constrained environment, the inefficiency and duplication of the drug research and development (R&D) paradigm is an indulgence we can no longer afford

Brought by:

Site Map | Best viewed at 1024x768 resolution. | © Copyright BASIS CORPORATION SDN. BHD. (315708-X). | | Share
Customer Notice and Summary of Rights | Personal Data Protection Policy   17-03-2018 10:33 PM